Director of Research at the Dept. of Haematology, Uni. of Cambridge
Dr. Helen Lee received her Ph.D. from Cornell University and MSc from Oxford University. She began her career in diagnostics at the Centre National de Transfusion Sanguine in Paris where she was responsible for developing monoclonal blood typing reagents, the first widely used liquid blood typing reagents in Paris. Another major accomplishment of her group was one of the first monoclonal antibody based assays for hepatitis B surface antigen. She then joined Abbott Laboratories to be responsible for Research & Development, and was promoted to General Manager of the Probe Diagnostics Business Unit where she managed over 100 people and an annual budget of >$20 million. She was also responsible for production of instruments as well as chemistry, marketing, quality and regulatory affairs of the product line. After leaving Abbott she founded a biotech company, Sentinel Biosciences Inc. in Palo Alto, CA, developing technologies for virus discovery. The company was successfully sold to one of the world’s largest pharmaceutical companies. In 1996, she left industry for the University of Cambridge in order to focus on the development of technology and diagnostic assays for resource-poor settings. She founded the spin off company, Diagnostics for the Real World Ltd (DRW), in 2002.